Navigation Links
BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
Date:7/28/2011

rious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, including, without li
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
2. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
3. BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET
4. BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
5. BioMarin to Present at the Barclays Capital Global Healthcare Conference
6. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
7. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
8. BioMarin to Present at the Morgan Stanley Healthcare Conference
9. BioMarin to Present at the Baird Healthcare Conference
10. BioMarin to Present at the Jefferies Healthcare Conference
11. BioMarin to Present at the Goldman Sachs Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces ... available in its catalogue: Global ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About ... that are readily decomposed by the action ... non-degradable packaging in terms of raw materials, ...
(Date:8/27/2014)... DUBLIN , Aug. 27, 2014 ... of the "Global Lactic Acid  (Biodegradable Polymer, ... - Trends & Forecasts to 2019" report ... the simplest hydroxyl-carboxylic acid with an asymmetrical carbon ... in the biodegradable polymer, food and beverage, personal ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
(Date:8/27/2014)... JUNCTION, N.J. , Aug. 27, 2014 ... innovative drug delivery technologies, today announced that it has ... Jersey Business & Industry Association,s 2014 Awards for ... were selected by an independent panel of judges from ... company volunteers. Award winners will be honored at a ...
Breaking Biology Technology:Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... the Wisconsin Technology Council have released a report detailing ... the difficulties that still need to be addressed to ... ,Wisconsin Technology Council President Tom Still pointed out ... have lost 10 to 15 percent of their technology ...
... study reported in the June 2005 issue of ... predominant. But many companies, even in people businesses, ... need to excel. While organizations have perfected sophisticated ... production and flow of goods and services, their ...
... optimistic that his bill requiring notification of electronic ... year. , ,Senate Bill 164, co-authored by ... require companies that keep personal data on customers ... data is obtained by unauthorized parties. Kanavas said ...
Cached Biology Technology:Report: Wisconsin still lags in college degrees held by workforce, leads elsewhere 2Report: Wisconsin still lags in college degrees held by workforce, leads elsewhere 3Four steps to making talent management a core competence 2Four steps to making talent management a core competence 3Four steps to making talent management a core competence 4Kanavas thinks personal ID theft bill will pass this year 2
(Date:8/27/2014)... of Warwick research finds , Gamblers show the ... new research has shown. , Researchers, led by Dr ... Psychology, conducted tests that found that both human gamblers ... high-value than low-value rewards. , Published in Biology ... show the important role that memories of previous biggest ...
(Date:8/26/2014)... developed algorithms to identify weak spots in tendons, muscles ... which needs to be refined before it is used ... and tiny injuries in the body,s tissues long before ... Aug. 27 in the Journal of the Royal ... of the physical and life sciences. , "Tendons are ...
(Date:8/26/2014)... of Warwick have provided the first evidence that ... linked to early signs of dementia. , Published ... that the absence of the protein MK2/3 promotes ... nervous system. These changes were shown to have ... including restricted learning and memory formation capabilities. , ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Lack of naturally occuring protein linked to dementia 2
... Europe,s first personalized treatment for lung cancer heralds the ... that will demand significant changes to the way cancer ... said today at the 2nd European Lung Cancer Conference ... Medical University of Vienna said that personalized therapy, in ...
... first trial of an important new combination therapy of ... in lung cancer has delivered promising results, French researchers ... The results of the Phase I trial suggest ... well-enough tolerated to allow it to be administered at ...
... allows precise targeting of radiotherapy using real-time X-ray images has ... administered to lung and liver cancers while minimizing harm to ... Cancer Conference. "With this study we show that it ... that can give information at any time before or during ...
Cached Biology News:Making personalized lung cancer therapy a reality in Europe 2First trial of pemetrexed with radiation and chemo in lung cancer shows promising results 2
... Pipette Tracker is an automated solution ... calibration and performance testing for all pipettes ... directly from any balance Supports ... ISO 8655, DIN 12650, ISO 9000, NCCLS ...
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
Biology Products: